Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Epidemiological Survey of the Patients With Bullous Pemphigoid Hospitalized in Alzahra Hospital, Isfahan, Iran, During the Years 2006-2015 Publisher

Summary: Study in Iran finds bullous pemphigoid, a blistering disease, hits women more, with high relapse and mortality rates, needing close monitoring. #AutoimmuneDisease #SkinHealth

Mokhtari F1 ; Iraji F1 ; Radfar S2 ; Asilian A1 ; Faghihi G1 ; Hosseini SM3
Authors

Source: Journal of Isfahan Medical School Published:2019


Abstract

Background: Bullous pemphigoid is one of the most common autoimmune blistering diseases. Incidence of bullous pemphigoid has been estimated 4 new cases per 100000, but new studies show that the incidence rate is increasing. The disease typically happens in the elderly people usually after 70 years. Annual mortality rate for bullous pemphigoid is reported up to 40%. The aim of this study was to evaluate epidemiological features of bullous pemphigoid in center of Iran. Methods: This was a cross-sectional study conducted in Alzahra hospital in Isfahan City. 69 patients with bullous pemphigoid hospitalized during the years 2008-2016 were studied. Findings: 59.45% of the patients were women. The mean and standard deviation of age was 68 ± 13 and 72 ± 14 years in woman and men, respectively (P = 0.01). Mucosal involvement was seen in 55.4%., and the most common underlying disease was hypertension (23.6%). 15.4% of women and 3.7% of men used furosemide, and the most commonly prescribed drugs were antihistamine (98%), antibiotics (97%), and topical (91%) and systemic (88.4%) corticosteroids, respectively. The mean and standard deviation of the dose of prednisolone was 54 ± 12 mg per day. Rise in serum blood sugar was reported in 30% of patients, and 3.6% of men and 15% of women needed intensive care unit (ICU) admission. 42.9% of men and 44.4% of women had relapse after discharge, and 38.64% of patients died during one-year follow-up. Conclusion: It seems that patients with bullous pemphigoid need careful follow up, especially during treatment, and at least for one year, because of their age (> 60), underlying diseases, type of treatment (corticosteroid use), and high mortality and relapsing rates in the first year after diagnosis. © 2019, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Interventions for Bullous Pemphigoid: An Updated Systematic Review of Randomized Clinical Trials, Medical Journal of the Islamic Republic of Iran (2021)
2. Demographic, Clinical, and Paraclinical Characteristics of Patients With Pemphigus Vulgaris Needing Hospital Admission During the Years 2006-2017, Journal of Isfahan Medical School (2018)
3. Frequency and Correlation of Peripheral and Tissue Eosinophilia With Clinical Manifestations in Patients With Bullous Pemphigoid, Dermatology Practical and Conceptual (2024)
Experts (# of related papers)
View all Related Experts
Gita Faghihi (5)
Ali Asilian (5)
Epidemiological Survey of the Patients With Bullous Pemphigoid Hospitalized in Alzahra Hospital, Isfahan, Iran, During the Years 2006-2015
Other Related Docs
4. Successful Treatment of Pemphigus Vulgaris With the Extensive Mucocutaneous Lesions in an Elderly Patient, Iranian Red Crescent Medical Journal (2014)
5. Pemphigus Vulgaris in Iran: Epidemiology and Clinical Profile., Skinmed (2006)
6. The Use of Oral Cyclophosphamide With Dexamethasone Pulse Therapy in the Treatment of Pemphigus Vulgaris, Journal of Dermatological Treatment (2007)
7. The Effect of L-Carnitine Supplementation on Serum Levels of Omentin-1, Visfatin and Sfrp5 and Glycemic Indices in Patients With Pemphigus Vulgaris: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Phytotherapy Research (2020)
8. Evaluation of Interleukin-1Α, Interleukin-10, Tumor Necrosis Factor-Α and Transforming Growth Factor-Β in the Serum of Patients With Pemphigus Vulgaris, Journal of Contemporary Dental Practice (2015)
9. Bullous Pemphigoid in a Renal Transplant Recipient, a Case Report and Review of the Literature, Iranian Journal of Kidney Diseases (2020)
10. Comparison Between the Efficacy of Intralesional Rituximab Versus Intralesional Triamcinolone in the Treatment Refractory Pemphigus Vulgaris Lesions: A Randomized Clinical Trial, International Immunopharmacology (2019)
11. An Unusual Ten-Like Presentation of Juvenile Bullous Pemphigoid: A Diagnostic Challenge, Case Reports in Dermatological Medicine (2022)
12. Immunohistochemistry for Immunoglobulin G4 in the Diagnosis of Pemphigus, Indian Journal of Dermatology (2019)
13. Adrenocorticotropic Hormone (Acth) Level and Adrenal Deficiency in Patients With Mucocutaneous Pemphigus, Hormone Molecular Biology and Clinical Investigation (2022)
14. Pimecrolimus 1% Cream in the Treatment of Cutaneous Lesions of Pemphigus Vulgaris: A Double-Blind, Placebo-Controlled Clinical Trial, Journal of Drugs in Dermatology (2010)
15. The Efficacy of Acyclovir in Treatment of the Pemphigus Vulgaris, Journal of Research in Medical Sciences (2013)